Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $67.75

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned a consensus recommendation of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. Ten investment analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $67.75.

JSPR has been the subject of a number of analyst reports. BMO Capital Markets began coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. HC Wainwright dropped their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday, January 6th. Finally, Royal Bank of Canada dropped their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a report on Thursday, January 9th.

Jasper Therapeutics Stock Up 1.9 %

Jasper Therapeutics stock opened at $5.78 on Friday. Jasper Therapeutics has a 52-week low of $5.25 and a 52-week high of $31.01. The firm has a market cap of $86.70 million, a PE ratio of -1.22 and a beta of 2.18. The company’s 50 day moving average is $17.08 and its two-hundred day moving average is $18.83.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.15). On average, equities research analysts anticipate that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in JSPR. BNP Paribas Financial Markets grew its holdings in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after buying an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter worth $59,000. MetLife Investment Management LLC grew its position in Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after buying an additional 3,873 shares during the last quarter. Jane Street Group LLC purchased a new position in Jasper Therapeutics during the 3rd quarter worth $251,000. Finally, Rhumbline Advisers acquired a new stake in shares of Jasper Therapeutics in the 2nd quarter worth $300,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.